

Supplementary Table 1. Comparison of clinical parameters with respect to a LS BMD z-score of -2.0

Variable	LS BMD z-score > -2.0 (n=22)	LS BMD z-score ≤ -2.0 (n=7)	P-value
Serological markers related to disease activity of SLE and bone metabolism			
At diagnosis			
C3 (mg/dL)	52.5 (30.5–87.8)	74.9 (67.5–107.5)	0.070
C4 (mg/dL)	6.5 (4.3–12.2)	7.4 (5.7–16.5)	0.524
Anti-ds DNA Ab (IU/mL)	111.4 (12.5–356.6)	195.8 (96.7–295.6)	0.305
Calcium (mg/dL)	8.9 (8.3–9.3)	9.0 (8.6–9.3)	0.627
Phosphorous (mg/dL)	3.9 (3.4–4.4)	3.9 (3.4–4.4)	0.898
Alkaline phosphatase (U/L)	80 (54.5–108.3)	108 (78.0–192.5)	0.168
Parathyroid hormone (pg/mL)	25.3 (22.9–28.6)	24.2 (23.3–32.6)	0.921
25(OH)VitD (ng/mL)	20.6 (14.1–26.6)	26.6 (24.5–27.1)	0.376
Follow-up			
C3 (mg/dL)	80.5 (72.3–99.5)	90 (77–103)	0.610
C4 (mg/dL)	11.8 (6.8–17.4)	14.8 (8.2–16.8)	1.000
Anti-ds DNA Ab (IU/mL)	18.3 (10.1–169.2)	60.1 (17.8–107.2)	0.779
SLEDAI score	4 (2.0–7.5)	4 (2.0–6.5)	0.837
Calcium (mg/dL)	9.2 (8.7–9.5)	9.2 (9.1–9.6)	0.306
Phosphorous (mg/dL)	4.3 (3.3–4.9)	4 (3.6–4.5)	0.759
Alkaline phosphatase (U/L)	79 (47–100.8)	93 (75.5–128.5)	0.429
Parathyroid hormone (pg/mL)	28.5 (23.3–45)	23.7 (22.2–30.3)	0.484
25(OH)VitD (ng/mL)	19.1 (14.1–26.5)	25.5 (24.2–28.9)	0.196

Values are presented as median (interquartile range).

LS lumbar spine; BMD, bone mineral density; SLE, systemic lupus erythematosus; Anti-ds DNA Ab, anti-double stranded DNA antibody; 25(OH)VitD, 25-hydroxy vitamin D; SLEDAI, systemic lupus erythematosus disease activity index.

Supplementary Table 2. Comparison of medication use with respect to a LS BMD z-score of -2.0

Variable	LS BMD z-score > -2.0 (n=22)	LS BMD z-score ≤ -2.0 (n=7)	P-value
Glucocorticoids			
Use ever	22 (100)	7 (100)	1.0
Duration (yr)	2.9 (1.8–5.2)	6.9 (5.1–9.4)	0.002
Cumulative dose (g)	12.3 (7.7–23.2)	26.8 (15.4–54.6)	0.021
Cumulative dose per mean body weight (g/kg)	0.23 (0.17–0.41)	0.54 (0.31–1.29)	0.027
Daily dose (mg/kg/day)	0.22 (0.15–0.36)	0.22 (0.18–0.34)	0.55
Disease-modifying antirheumatic drugs			
Hydroxychloroquine use ever	22 (100)	7 (100)	1.0
Cumulative dose (g/kg)	4.64 (1.75–8.19)	10.1 (8.17–12.17)	0.003
Azathioprine use ever	10 (45.5)	6 (85.7)	0.062
Methotrexate	6 (27.3)	4 (57.1)	0.148
Mycophenolate mofetil use ever	5 (22.7)	4 (57.1)	0.086
Cyclosporine use ever	2 (9.1)	1 (14.3)	0.694
Antiosteoporosis therapies			
Vitamin D use ever	12 (54.5)	6 (85.7)	0.139
Calcium supplements use ever	5 (22.7)	4 (57.1)	0.086
Bisphosphonates use ever	0 (0)	4 (57.1)	<0.001

Values are presented as number (%) or median (interquartile range).

LS, lumbar spine; BMD, bone mineral density